BeiGene Ltd (SHSE:688235)
Â¥ 121.47 -4.8 (-3.8%) Market Cap: 117.80 Bil Enterprise Value: 105.51 Bil PE Ratio: 0 PB Ratio: 4.75 GF Score: 55/100

Beigene Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 10, 2022 / 02:00PM GMT
Release Date Price: ¥118.36 (+1.62%)
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

Welcome. My name is Michael Schmidt. I'm one of the biotech analysts at Guggenheim and it is my great pleasure to welcome the next company, BeiGene. With us today, we have John Oyler, Co-Founder and CEO. John, thanks so much for joining us and welcome.

John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO

Thanks, happy to be here.

Questions & Answers

Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

So I think I'll just start with a big picture question. BeiGene is obviously now one of the largest global biotech companies. Perhaps, John, if you -- could you briefly just highlight how the strategy of the company has been in recent years?

John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO

Sure. Happy to do that. I think BeiGene started about 12 years ago. And from the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot